PAVmed Inc (NASDAQ:PAVM) CEO Dr. Lishan Aklog tells Proactive the New York-based diversified medical device group has recently commercially launched three of its medical device products, two of which come from its subsidiary, Lucid Diagnostics.
Dr. Aklog says the group is beginning see payments on the products, with Medicare payment approval given in January 2021. With its recently raised capital of $45M, the group will look to expand commercial activity within Lucid Diagnostics.